14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
LIVN vs UFPT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). LIVN carries a Unified Composite Score of 32.7/100 (SELL) at $92.44 (19.5x Forward P/E, 14.3% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin).
Composite vs. Pillar Nuance: While UFPT currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. LIVN 32.7/100 SELL), LIVN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 15.4% operating margin) and revenue trajectory (+9.9% vs. +11.6% YoY).
Technical & Structure Timing Caution: LIVN trades in a Markup technical trend (BREAKOUT options phase, RSI 66.8); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LIVN vs UFPT. Trailing 12-month operating profitability (LIVN 14.3% vs UFPT 15.4%) and valuation multiples (LIVN 19.5x vs UFPT 24.7x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment13.5% of Rev ($88M)
90D Engineering Disclosures0 Published
Investor FAQ LIVN vs UFPT Key Questions & Quantitative Answers
As of Nov 16, 2026, LivaNova PLC (LIVN) is the stronger overall head-to-head candidate over UFP Technologies Inc (UFPT) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Options & Positioning, R&D & Supply-Chain Moat). LIVN carries a Unified Composite Score of 32.7/100 (SELL) at $92.44 (19.5x Forward P/E, 14.3% operating margin), whereas UFPT carries 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin). Composite vs. Pillar Nuance: While UFPT currently prints a higher short-term Unified Composite Score (42.6/100 HOLD vs. LIVN 32.7/100 SELL), LIVN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (14.3% vs. 15.4% operating margin) and revenue trajectory (+9.9% vs. +11.6% YoY). Technical & Structure Timing Caution: LIVN trades in a Markup technical trend (BREAKOUT options phase, RSI 66.8); meanwhile UFPT is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
UFPT leads the Growth & Scale pillar: LIVN posts +9.9% YoY revenue growth and -78.2% YoY earnings growth on $1.51B TTM revenue (67.6% gross margin, 14.3% operating margin), compared with UFPT at +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin). On trailing 12-month operating scale, LIVN generates $1.51B in USD-normalized revenue versus $650M for UFPT. In operating R&D and SG&A reinvestment, LIVN deploys 53.3% of Rev ($803M) (0 90-day corporate R&D disclosures) versus 13.5% of Rev ($88M) (0 disclosures) for UFPT.
LIVN screens cheaper on headline valuation multiples. LIVN trades at 19.5x Forward P/E, 26.2x Trailing P/E, 0.93x PEG, and 3.2x EV/Revenue (8.6% FCF margin), whereas UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LIVN (15.5% ROE) versus UFPT (17.2% ROE) capital efficiency.
In options market volatility and institutional positioning, LIVN carries 57.7% implied volatility (17th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.02β · 67% Vol realized risk). By comparison, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.